MedTrace Logo

The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery

NCT01831154 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2017-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to investigate the effects of three different glycemic treatment conditions (tight, conventional, and standard) in the intraoperative period on: 1) postoperative surgical site infections, and 2) postoperative procalcitonin, and C-reactive protein levels in patients undergoing open-heart surgery. Secondary aims of the study were to investigate the effects of the three glycemic treatment conditions on: 1) intraoperative blood glucose; 2) intraoperative glycemic stability; and 3) intensive care unit length of stay, in patients undergoing open-heart surgery.

Conditions

Interventions

DRUG

Tight Glycemic

The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.

DRUG

Conventional Glycemic

The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.

DRUG

Standard Glycemic

Insulin was Regular Insulin administered intravenous bolus.

Sponsors & Collaborators

  • University of South Florida

    collaborator OTHER

  • James A. Haley Veterans Administration Hospital

    lead FED

Principal Investigators

  • Sierra A Gower, PhD · James A Haley VAH

  • Theresa Beckie, PhD · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-07-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01831154 on ClinicalTrials.gov